Shares of cancer-focused biotechs Bluebird Bio, Clovis Oncology and Kite Pharma popped Tuesday, leading a sectorwide boom that eventually settled toward the close.
At the close on the stock market today, IBD’s 433-company Biomed/Biotech industry group ticked up 1% , hitting a high last seen in mid-March.
Bluebird stock lifted 0.3%, near 113, continuing a strong run that began in the first week of June when the small-cap biotech presented data with Celgene in a trial of patients with a blood cancer known as multiple myeloma.
